Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy

被引:207
作者
Maron, Barry J. [1 ]
Spirito, Paolo [2 ]
Ackerman, Michael J. [3 ]
Casey, Susan A. [1 ]
Semsarian, Christopher [4 ,5 ]
Estes, N. A. Mark, III [6 ,7 ]
Shannon, Kevin M. [8 ]
Ashley, Euan A. [9 ,10 ]
Day, Sharlene M. [11 ]
Pacileo, Giuseppe [12 ]
Formisano, Francesco [2 ]
Devoto, Emmanuela [2 ]
Anastasakis, Aristidis [13 ]
Bos, J. Martijn [3 ]
Woo, Anna [14 ]
Autore, Camillo [15 ]
Pass, Robert H. [16 ]
Boriani, Giuseppe [17 ]
Garberich, Ross F. [1 ]
Almquist, Adrian K. [1 ]
Russell, Mark W. [11 ]
Boni, Luca [18 ]
Berger, Stuart [19 ]
Maron, Martin S. [6 ,7 ]
Link, Mark S. [6 ,7 ]
机构
[1] Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN 55407 USA
[2] Ente Osped Osped Galliera, Genoa, Italy
[3] Mayo Clin, Rochester, MN USA
[4] Univ Sydney, Royal Prince Alfred Hosp, Sydney, NSW 2006, Australia
[5] Univ Sydney, Centenary Inst, Sydney, NSW 2006, Australia
[6] Tufts Med Ctr, Boston, MA USA
[7] Sch Med, Boston, MA USA
[8] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[9] Stanford Univ Hosp, Palo Alto, CA USA
[10] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[11] Univ Michigan Hlth Syst, Mott Childrens Hosp, Ann Arbor, MI USA
[12] Univ Naples 2, Monaldi Hosp, Naples, Italy
[13] Univ Athens, Dept Cardiol, Athens, Greece
[14] Toronto Gen Hosp, Toronto, ON, Canada
[15] Univ Roma La Sapienza, Dept Clin & Mol Med, Rome, Italy
[16] Childrens Hosp Montefiore, Bronx, NY USA
[17] Univ Bologna, Inst Cardiol, S Orsola Malpighi Hosp, Bologna, Italy
[18] Ist Toscano Tumori AOU Careggi, Clin Trials Coordinating Ctr, Florence, Italy
[19] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA
关键词
cardiomyopathy; children; defibrillators; sudden death; ventricular fibrillation; HIGH-RISK; THERAPY; STRATIFICATION; SURROGATE; EFFICACY; OUTCOMES;
D O I
10.1016/j.jacc.2013.01.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this study was to determine the efficacy of implantable cardioverter-defibrillators (ICDs) in children and adolescents with hypertrophic cardiomyopathy (HCM). Background HCM is the most common cause of sudden death in the young. The availability of ICDs over the past decade for HCM has demonstrated the potential for sudden death prevention, predominantly in adult patients. Methods A multicenter international registry of ICDs implanted (1987 to 2011) in 224 unrelated children and adolescents with HCM judged at high risk for sudden death was assembled. Patients received ICDs for primary (n = 188) or secondary (n = 36) prevention after undergoing evaluation at 22 referral and nonreferral institutions in the United States, Canada, Europe, and Australia. Results Defibrillators were activated appropriately to terminate ventricular tachycardia or ventricular fibrillation in 43 of 224 patients (19%) over a mean of 4.3 +/- 3.3 years. ICD intervention rates were 4.5% per year overall, 14.0% per year for secondary prevention after cardiac arrest, and 3.1% per year for primary prevention on the basis of risk factors (5-year cumulative probability 17%). The mean time from implantation to first appropriate discharge was 2.9 +/- 2.7 years (range to 8.6 years). The primary prevention discharge rate terminating ventricular tachycardia or ventricular fibrillation was the same in patients who underwent implantation for 1, 2, or >= 3 risk factors (12 of 88 [14%], 10 of 71 [14%], and 4 of 29 [14%], respectively, p = 1.00). Extreme left ventricular hypertrophy was the most common risk factor present (alone or in combination with other markers) in patients experiencing primary prevention interventions (17 of 26 [65%]). ICD-related complications, particularly inappropriate shocks and lead malfunction, occurred in 91 patients (41%) at 17 +/- 5 years of age. Conclusions In a high-risk pediatric HCM cohort, ICD interventions terminating life-threatening ventricular tachyarrhythmias were frequent. Extreme left ventricular hypertrophy was most frequently associated with appropriate interventions. The rate of device complications adds a measure of complexity to ICD decisions in this age group. (J Am Coll Cardiol 2013;61:1527-35) (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:1527 / 1535
页数:9
相关论文
共 38 条
[1]   Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients [J].
Alsheikh-Ali, Alawi A. ;
Link, Mark S. ;
Semsarian, Christopher ;
Shen, Win-Kuang ;
Estes, N. A. Mark, III ;
Maron, Martin S. ;
Haas, Tammy S. ;
Formisano, Francesco ;
Boriani, Giuseppe ;
Spirito, Paolo ;
Maron, Barry J. .
HEART RHYTHM, 2013, 10 (02) :214-218
[2]   Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy [J].
Begley, DA ;
Mohiddin, SA ;
Tripodi, D ;
Winkler, JB ;
Fananapazir, L .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2003, 26 (09) :1887-1896
[3]   Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients [J].
Berul, Charles I. ;
Van Hare, George F. ;
Kertesz, Naomi J. ;
Dubin, Anne M. ;
Cecchin, Frank ;
Collins, Kathryn K. ;
Cannon, Bryan C. ;
Alexander, Mark E. ;
Triedman, John K. ;
Walsh, Edward P. ;
Friedman, Richard A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (17) :1685-1691
[4]   Prevention of sudden death in hypertrophic cardiomyopathy - But which defibrillator for which patient? [J].
Boriani, G ;
Maron, BJ ;
Shen, WK ;
Spirito, P .
CIRCULATION, 2004, 110 (15) :E438-E442
[5]   Role of Family History of Sudden Death in Risk Stratification and Prevention of Sudden Death With Implantable Defibrillators in Hypertrophic Cardiomyopathy [J].
Bos, J. Martijn ;
Maron, Barry J. ;
Ackerman, Michael J. ;
Haas, Tammy S. ;
Sorajja, Paul ;
Nishimura, Rick A. ;
Gersh, Bernard J. ;
Ommen, Steve R. .
AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106 (10) :1481-1486
[6]   Use and misuse of surrogate outcomes in arrhythmia trials [J].
Connolly, SJ .
CIRCULATION, 2006, 113 (06) :764-766
[7]   Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? [J].
Ellenbogen, KA ;
Levine, JH ;
Berger, RD ;
Daubert, JP ;
Winters, SL ;
Greenstein, E ;
Shalaby, A ;
Schaechter, A ;
Subacius, H ;
Kadish, A .
CIRCULATION, 2006, 113 (06) :776-782
[8]   Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients [J].
Elliott, PM ;
Poloniecki, J ;
Dickie, S ;
Sharma, S ;
Monserrat, L ;
Varnava, A ;
Mahon, NG ;
McKenna, WJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2212-2218
[9]   2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J].
Gersh, Bernard J. ;
Maron, Barry J. ;
Bonow, Robert O. ;
Dearani, Joseph A. ;
Fifer, Michael A. ;
Link, Mark S. ;
Naidu, Srihari S. ;
Nishimura, Rick A. ;
Ommen, Steve R. ;
Rakowski, Harry ;
Seidman, Christine E. ;
Towbin, Jeffrey A. ;
Udelson, James E. ;
Yancy, Clyde W. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (25) :E212-E260
[10]   Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy [J].
Harris, Kevin M. ;
Spirito, Paolo ;
Maron, Martin S. ;
Zenovich, Andrey G. ;
Formisano, Francesco ;
Lesser, John R. ;
Mackey-Bojack, Shannon ;
Manning, Warren J. ;
Udelson, James E. ;
Maron, Barry J. .
CIRCULATION, 2006, 114 (03) :216-225